Results 51 to 60 of about 6,898 (170)

In Silico Pharmacokinetic Profile and Antimalarial Efficacy of 3‐Chloro‐4‐(4‐Chlorophenoxy)Aniline

Biochemistry Research International, Volume 2026, Issue 1, 2026.
Despite the urgent need for new therapies to treat multidrug‐resistant virulent Plasmodium falciparum, many promising antimalarial candidates fail to progress to clinical use because their pharmacokinetic (PK) profile is poorly characterized. This study predicted the PK profile of a new compound, 3‐chloro‐4‐(4‐chlorophenoxy)aniline (ANI), in silico ...
Milka W. Waithera, Shadrack K. Kimani, Stephen Njoroge, Thomas Nyahanga, Johnson K. Kinyua, Harleen Khatra   +5 more
wiley   +1 more source

Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali

Malaria Journal, 2009
Background To update the National Malaria Control Programme of Mali on the efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria.
Wele Mamadou, Dembele Demba, Kone Aminatou, Dama Souleymane, Ouologuem Dinkorma, Fofana Bakary, Sagara Issaka, Maiga Hamma, Beavogui Abdoul H, Djimde Abdoulaye A, Tekete Mamadou, Dicko Alassane, Doumbo Ogobara K   +12 more
doaj   +1 more source

Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change

The Pan African Medical Journal, 2020
INTRODUCTION: Artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first line therapy of uncomplicated malaria in Burkina Faso. We assessed the treatment efficacy, tolerability of these drugs 11 years following its adoption as first ...
Issaka Zongo, Yves Daniel Compaoré, Frédéric Nikiéma, Moussa Zongo, Nouhoun Barry, Fabrice Anyirékun Somé, Naomie Kaboré, Jean Bosco Ouédraogo   +7 more
doaj   +1 more source

Unveiling Antimalarial Drug Resistance: The Role of CRISPR‐Cas Technologies in Malaria Research

Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Background Malaria, caused by Plasmodium parasites, remains a global health burden, with drug resistance threatening control efforts. CRISPR‐Cas technologies, particularly CRISPR‐Cas9, have transformed malaria research by enabling precise genetic manipulations to study antimalarial resistance mechanisms, develop novel therapeutics and enhance ...
Reuben Samson Dangana, Israel Ehizuelen Ebhohimen, Moses Okpeku, Jess Vergis   +3 more
wiley   +1 more source

Pharmacological, Phytochemical, and Toxicological Evaluation of the Ethanolic Extract of Alstonia boonei (Apocynaceae) Toward Antimalarial Phytodrug Development

Journal of Chemistry, Volume 2026, Issue 1, 2026.
Despite ongoing efforts, malaria persists as a significant health challenge in developing countries. This study aims to investigate the antimalarial potential of Alstonia boonei stem bark, a traditional plant in Cameroon. The EtOH‐H2O (70:30) extract was subjected to phytochemical screening and chromatographic isolation of compounds.
Diane K. Nono, Rachel L. Y. Tchoukouaha, Armelle D. Tchamgoue, Hermia N. Ikome, Godfred A. Ayimele, Protus A. Tarkang, Denis Zofou, Olivia Jansen, Michel Frédérich, Gabriel A. Agbor, Augustin Nkengfack, Alembert T. Tchinda, Sohini Basu Roy   +12 more
wiley   +1 more source

Antimalarial Drugs-Induced Hepatic Injury in Rats and the Protective Role of Carnosine

Pharmaceutical Sciences, 2016
Background: Chloroquine and amodiaquine are used in the prophylaxis and treatment of malaria. However, hepatic injury is associated with malaria drug therapy. On the other hand, there is no promising hepatoprotective agent for prophylaxis or treatment of
Akram Jamshidzadeh, Reza Heidari, Farzaneh Abazari, Maral Ramezani, Forouzan Khodaei, Mohammad Mehdi Ommati, Maryam Ayarzadeh, Roya Firuzi, Arastoo Saeedi, Negar Azarpira, Asma Najibi
doaj   +1 more source

Amodiaquine

, 2006
europepmc   +2 more sources

Preparation and evaluation of mixed-ligand complexes of Cu (II) and Co (II) with amodiaquine hydrochloride and sulphamethazine

Journal of Applied Sciences and Environmental Management, 2018
Cu (ll) and Co (II) complexes of amodiaquine hydrochloride and sulphamethazine (AMOSUF) have been prepared and characterized by elemental analysis, molar conductivity, FTIR and electronic spectroscopy.
E.A. Enemose, E.E. Akporhonor, B Kpomah
doaj   +1 more source

Amodiaquine Modulates Aggregation and Disassembly of Amyloid-β and Tau and Attenuates Neuroinflammatory Responses and Aβ Production

Pharmaceutics
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) plaques and hyperphosphorylated tau tangles, which synergistically accelerate disease progression.
Sinae Jang, Sujin Kim, Na-Hyun Kim, Soo Jung Shin, Vijay Kumar, Jeong Gyu Son, Minseok Lee, Choon-gil Kim, Eun-Kyung Lim, Hyunju Chung, Young Ho Koh, Yunkwon Nam, Minho Moon   +12 more
doaj   +1 more source

Efficacy of amodiaquine in the treatment of uncomplicated falciparum malaria in young children of rural north-western Burkina Faso

Malaria Journal, 2008
Background Combination therapy has become a new paradigm in malaria treatment. Amodiaquine is a common partner drug in different malaria combination therapies used or investigated in sub-Saharan Africa, but data on its efficacy as a single drug are ...
Meissner Peter, Coulibaly Boubacar, Mockenhaupt Frank P, Mandi Germain, Müller Olaf   +4 more
doaj   +1 more source